A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design
- PMID: 27645352
- DOI: 10.1016/j.msard.2016.07.002
A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design
Abstract
Background: GNbAC1, a humanized monoclonal antibody, is an innovative treatment currently in development for multiple sclerosis (MS) which, contrary to the immunomodulation/immunosuppressive mechanism of action of most of the MS drugs, targets specifically a protein of endogenous retroviral origin supposed to be critical in MS pathogenesis.
Methods: This trial is a randomized placebo controlled 4-arm study with the objective of demonstrating the efficacy of repeated doses of GNbAC1 on the cumulative number of T1 Gd-enhancing lesions measured from Week 12 to 24 in patients with relapsing remitting MS (RRMS). Two hundred sixty patients with RRMS are planned to be included. Three doses of GNbAC1 will be tested versus placebo: 6mg/kg, 12mg/kg and 18mg/kg, administered intravenously, with 4-week administration intervals. The design is based on the classic 24-week placebo-controlled repeated brain MRI trial design (Period 1), with an extension of 24 weeks during which placebo patients will be re-randomized to one of the three doses of GNbAC1 to assess efficacy and safety of prolonged treatment of GNbAC1 (Period 2). The primary endpoint is the cumulative number of new Gadolinium enhanced T1 lesions measured using repeated brain magnetic resonance imaging (MRI) scans from Week 12 to 24; secondary endpoints, including additional MRI and clinical endpoints, will be assessed at the end of both Periods 1 and 2. Pharmacokinetics and biomarkers will be assessed in serum in all patients at several time points and also in cerebrospinal fluid in a subgroup of patients. To alleviate potential ethical concerns regarding placebo administration in MS, an early escape from trial will be implemented for patients with a worsening clinical condition during trial.
Conclusion: This dose-finding study should provide the first proof-of-concept of an innovative therapeutic approach for MS. The constraints of using a placebo group in RRMS patients while optimizing the trial power to evidence a new mechanism of action is discussed.
Keywords: Endogenous retrovirus; Magnetic resonance imaging; Monoclonal antibody; Phase II study; Relapsing remitting multiple sclerosis.
Copyright © 2016 Elsevier B.V. All rights reserved.
Similar articles
-
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.Mult Scler. 2015 Jun;21(7):885-93. doi: 10.1177/1352458514554052. Epub 2014 Nov 12. Mult Scler. 2015. PMID: 25392325 Clinical Trial.
-
Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.J Neurol. 2016 Jul;263(7):1287-95. doi: 10.1007/s00415-016-8128-x. Epub 2016 May 3. J Neurol. 2016. PMID: 27142710 Clinical Trial.
-
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.Lancet Neurol. 2008 Sep;7(9):796-804. doi: 10.1016/S1474-4422(08)70173-X. Lancet Neurol. 2008. PMID: 18703004 Clinical Trial.
-
A new therapeutic approach for type 1 diabetes: Rationale for GNbAC1, an anti-HERV-W-Env monoclonal antibody.Diabetes Obes Metab. 2018 Sep;20(9):2075-2084. doi: 10.1111/dom.13357. Epub 2018 Jun 10. Diabetes Obes Metab. 2018. PMID: 29749030 Review.
-
Management of worsening multiple sclerosis with mitoxantrone: a review.Clin Ther. 2006 Apr;28(4):461-74. doi: 10.1016/j.clinthera.2006.04.013. Clin Ther. 2006. PMID: 16750460 Review.
Cited by
-
Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment.Front Neurol. 2022 Oct 14;13:980758. doi: 10.3389/fneur.2022.980758. eCollection 2022. Front Neurol. 2022. PMID: 36313502 Free PMC article. Review.
-
Immunogenicity of the Envelope Surface Unit of Human Endogenous Retrovirus K18 in Mice.Int J Mol Sci. 2022 Jul 28;23(15):8330. doi: 10.3390/ijms23158330. Int J Mol Sci. 2022. PMID: 35955468 Free PMC article.
-
Human Endogenous Retrovirus as Therapeutic Targets in Neurologic Disease.Pharmaceuticals (Basel). 2021 May 24;14(6):495. doi: 10.3390/ph14060495. Pharmaceuticals (Basel). 2021. PMID: 34073730 Free PMC article. Review.
-
Endogenous Retroviruses in Nervous System Disorders.Pharmaceuticals (Basel). 2021 Jan 16;14(1):70. doi: 10.3390/ph14010070. Pharmaceuticals (Basel). 2021. PMID: 33467098 Free PMC article. Review.
-
Close to the Bedside: A Systematic Review of Endogenous Retroviruses and Their Impact in Oncology.J Surg Res. 2019 Aug;240:145-155. doi: 10.1016/j.jss.2019.02.009. Epub 2019 Mar 29. J Surg Res. 2019. PMID: 30933828 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical